Drugs / 225Ac-MTI-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05496686 | Jul 2022 → Mar 2027 expected | metastatic melanoma, uveal melanoma | Modulation Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-MTI-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496686 ↗ |
| Known as | 225Actinium-MTI-201 | “First in Human Phase I Study of 225Actinium-MTI-201 (225Ac-MTI-201) in Metastatic Uveal Melanoma” NCT05496686 ↗ |
| Route | Intravenous | “The participants who meet the eligibility requirements will be administered a single intravenous dose of 225Ac-MTI-201.” NCT05496686 ↗ |